Essayer OR - Gratuit

Astronaut 634: Shux blends science, sweets and space

Business Standard

|

July 03, 2025

The name 'Shux'. Orbital flight number 634. Sleeping quarters: Dragon. And on the menu: Gajar ka halwa, moong dal halwa, and aam ras.

- SHINE JACOB Chennai, 2 July

Astronaut 634: Shux blends science, sweets and space

These personal details, both technical and cultural, could soon take their place in history books as symbols of India's return to human spaceflight, after a 41-year break.

Orbiting some 400 kilometers above Earth's surface at a speed of 8 kilometers per second, completing 16 orbits a day, Shubhanshu Shukla — 'Shux' to his crewmates — is now firmly embedded in the rhythms of life aboard the International Space Station (ISS). His first seven days on the Axiom Mission 4 (Ax-4) have combined science, ceremony, and moments of levity — from critical biomedical research to lighthearted exchanges over Indian sweets with the ISS Expedition 73 crew, and a nationally significant conversation with Prime Minister Narendra Modi.

Shukla's journey began on June 25 with a launch from NASA's Kennedy Space Center in Florida. He flew aboard a SpaceX Falcon 9 rocket in a Dragon capsule, as part of Ax-4. On June 26, the capsule docked with the ISS. A few hours earlier, the crew participated in an in-flight event from orbit, during which Shukla — one of the astronauts chosen for India's own human space flight programme, the Gaganyaan — described his excitement at seeing Earth from above while flying over Europe.

When Dragon finally latched onto the orbiting laboratory, NASA's Expedition 73 team welcomed the Ax-4 crew with a ceremonial flourish. Ax-4 commander Peggy Whitson presented astronaut lapel pins and assigned orbital flight numbers. Shukla received the golden pin in recognition of having flown to space and was designated orbital flight number 634 — making him the 634th person to travel around Earth in a spacecraft.

PLUS D'HISTOIRES DE Business Standard

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size